

1 **Acute Anti-allodynic Action of Gabapentin in Dorsal Horn and**
2 **Primary Somatosensory Cortex: Correlation of Behavioural**
3 **and Physiological Data.**

4
5 SASCHA R.A. ALLES¹, MISCHA V. BANDET, KATE EPPLER, MYUNG-CHUL NOH,
6 IAN R. WINSHIP, GLEN BAKER, KLAUS BALLANYI AND PETER A. SMITH.

7 *Neuroscience and Mental Health Institute (SRAS, MVB, IRW, GB, KB, PAS), Departments of*
8 *Psychiatry (IRW, GB), Physiology (KB) and Pharmacology (PAS, M-CN, KE) University of*
9 *Alberta, Edmonton, AB, Canada T6G 2H7.*

10

11 *Running Title:-* Cortical and Spinal Actions of Gabapentin

12

13 *Corresponding Author:-*

14 Peter A Smith, PhD

15 Department of Pharmacology and Neuroscience and Mental Health Institute

16 9.75 Medical Sciences Building, University of Alberta, Edmonton, AB T6G 2H7, CANADA

17 Phone + 1 780 492 2643 FAX + 1 780 492 4325 E-mail pas3@ualberta.ca

18

19 *Manuscript Properties:-*

20 43 Text Pages, 1 Table, 6 Figures (Figs 1 and 6 in colour) Abstract 250 Words,

21

22 *Abbreviations:-*

23 cHL Contralateral hind limb, CCI Chronic Constriction Injury, DRG Dorsal Root Ganglion, GBP

24 Gabapentin, IEI Inter-event Interval, IOS Intrinsic Optical Signal, PWT Paw Withdrawal Threshold,

25 S1 Primary Somatosensory Cortex

26

27 ¹*Present Address* Djavad Mowafaghian Centre for Brain Health and Michael Smith Laboratories,
28 University of British Columbia, #4541 - 2215 Wesbrook Mall, Vancouver BC, V6T 1Z3

29

30

31

1 **ABSTRACT**

2

3 Neuropathic pain is a debilitating consequence of neuronal injury or disease. Although
4 first line treatments include the alpha-2-delta ($\alpha 2\delta$)-ligands, pregabalin and gabapentin (GBP),
5 the mechanism of their anti-allodynic action is poorly understood. One specific paradox is that
6 GBP relieves signs of neuropathic pain in animal models within 30min of an intraperitoneal (IP)
7 injection yet its actions *in vitro* on spinal dorsal horn or primary afferent neurons take hours to
8 develop. We found, using confocal Ca^{2+} imaging, that *substantia gelatinosa* neurons obtained *ex*
9 *vivo* from rats subjected to sciatic chronic constriction injury (CCI) were more excitable than
10 controls. We confirmed that GBP (100mg/kg) attenuated mechanical allodynia in animals subject
11 to CCI within 30min of IP injection. *Substantia gelatinosa* neurons obtained *ex vivo* from these
12 animals no longer displayed CCI-induced increased excitability.

13 Electrophysiological analysis of *substantia gelatinosa* neurons *ex vivo* suggest that
14 rapidly developing *in vivo* anti-allodynic effects of GBP i) are mediated intracellularly, ii)
15 involve actions on the neurotransmitter release machinery and iii) depend on decreased
16 excitatory synaptic drive to excitatory neurons without major actions on inhibitory neurons or on
17 intrinsic neuronal excitability. Experiments using *in vivo* Ca^{2+} imaging showed that 100mg/kg
18 GBP also suppressed the response of the S1 somatosensory cortex of CCI rats, but not that of
19 control rats, to vibrotactile stimulation.

20 Since the level of $\alpha 2\delta 1$ protein is increased in primary afferent fibres after sciatic CCI,
21 we suggest this dictates the rate of GBP action; rapidly developing actions can only be seen
22 when $\alpha 2\delta 1$ levels are elevated.

23

24

1

2 **KEYWORDS**

3 Neuropathic Pain; Electrophysiology: *In vivo* calcium imaging; Alpha 2 delta; *Substantia*
4 *gelatinosa*; Synaptic transmission.

5

6 **HIGHLIGHTS**

7

- 8 • Gabapentin (GBP) relieves neuropathic pain in animal models within 30min
- 9 • Spinal cord slices obtained *ex vivo* from GBP-treated rats have reduced excitability
- 10 • Synaptic drive to excitatory *substantia gelatinosa* neurons is decreased
- 11 • GBP actions *in vivo* are mediated intracellularly
- 12 • GBP affects the neurotransmitter release machinery *in vivo*

13

1 **1. Introduction**

2 Injury to the somatosensory system can produce ‘neuropathic’ pain that lasts for months
3 or years after any injury has healed (Treede, et al., 2008;Costigan, et al., 2009;Berger et al.,
4 2011). This maladaptive ‘disease of pain’ has a 1.5-3% prevalence within the general population
5 (Torrance, et al., 2006) and can associate with diabetic, postherpetic or HIV-related
6 neuropathies, with multiple sclerosis or fibromyalgia as well as with traumatic nerve, spinal cord
7 or brain injury (including stroke). It is associated with marked disruption of sensory signaling at
8 the peripheral, spinal, thalamic and cortical levels (Sandkuhler, 2009;Zhuo, 2008;Patel and
9 Dickenson, 2016;Chen, et al., 2014a;Pitcher and Henry, 2008). Afflicted individuals exhibit
10 hyperalgesia, allodynia (the generation of a painful sensation by an innocuous stimulus) and
11 bouts of stimulus-independent “electric shock like” pain (Mogil, 2009). Some experience
12 causalgia (a persistent, burning pain).

13 Unfortunately, neuropathic pain is poorly responsive to opioid analgesics and this can
14 lead to over-prescription and abuse. Even the “ $\alpha 2\delta$ ligands”, pregabalin (PGB) and gabapentin
15 (GBP), which are first line treatments (Finnerup, et al., 2015) are not universally effective and as
16 many as 65% of patients fail to report appreciable pain relief (Moore, et al., 2014). To better
17 understand the mechanism of gabapentinoid action, we have addressed a paradox relating to their
18 time course of action. Accepted animal models of neuropathic pain include experimental lesion
19 of peripheral nerves such as sciatic chronic constriction (CCI) (Kim, et al., 1997;Mosconi and
20 Kruger, 1996) or spared nerve injury (SNI) (Decosterd and Woolf, 2000). In such models,
21 gabapentinoids attenuate hyperalgesia and/or allodynia within 30-60min of a parenteral injection
22 (Hunter, et al., 1997;Kayser and Christensen, 2000;Field, et al., 2006;Kumar, et al., 2013;Alles
23 and Smith, 2016;Luo, et al., 2002). Despite this, their reported actions on nociceptive neurons in

1 spinal cord or dorsal root ganglia (DRG) *in vitro* are 10-30 times slower; taking 10-15h to
2 develop (Hendrich, et al., 2008;Hendrich, et al., 2012;Biggs, et al., 2014).

3 Alpha-2-delta ($\alpha 2\delta$) refers to a family of accessory subunits that co-assemble with the
4 pore forming α -subunits of high voltage-gated (HVA) Ca^{2+} channels (Dolphin, 2013;Dolphin,
5 2012;Zamponi, et al., 2015;Dolphin, 2016). One such subunit, $\alpha 2\delta$ -1 is upregulated in the DRG
6 of animals subject to peripheral nerve injury and this coincides with the onset of signs of
7 neuropathic pain (Luo, et al., 2001;Luo, et al., 2002;Bauer, et al., 2009). Pain behaviors also
8 appear in animals genetically engineered to overexpress $\alpha 2\delta$ -1 (Li, et al., 2006;Li, et al., 2004).
9 Gabapentinoids are transported into the neuronal cytoplasm, where they bind to $\alpha 2\delta$ -1 subunits
10 (Gee, et al., 1996;Field, et al., 2006;Lana, et al., 2016;Field, et al., 2006;Hendrich, et al.,
11 2008;Lana, et al., 2016). This interaction interferes with both the trafficking of $\alpha 2\delta$ -1 between
12 the DRG cell body and primary afferent terminal (Bauer, et al., 2009) and the local trafficking of
13 $\alpha 2\delta$ -1 subunits and their associated, pore forming α -subunits between the endoplasmic reticulum
14 and the cell surface (Hendrich et al., 2008). Within nerve terminals, this impedes the ability of
15 HVA- Ca^{2+} channels to interact with the vesicle fusion machinery for neurotransmitter release
16 (Hoppa, et al., 2012). This leads to attenuation of synaptic transmission between nociceptive
17 primary afferents and second order sensory neurons in the spinal dorsal horn (Hendrich, et al.,
18 2012;Biggs, et al., 2014). It has been suggested that gabapentinoids antagonize the actions of the
19 novel neurotrophin, thrombospondin 4 which also binds $\alpha 2\delta$ (Pan, et al., 2016;Lana, et al., 2016).

20 Studies that failed to observe a rapidly developing, acute action of GBP *in vitro* (Moore,
21 et al., 2002;Biggs, et al., 2014;Hendrich, et al., 2008) were done on dorsal horn neurons from
22 naive animals rather than those subject to nerve injury. To the best of our knowledge, there are
23 no studies of the acute antiallodynic action of gabapentinoids in the chronic constriction injury

1 (CCI) or spared nerve injury (SNI) model of neuropathic pain (Mosconi and Kruger,
2 1996;Decosterd and Woolf, 2000) that are correlated with changes in dorsal horn neurons.
3 Furthermore, no attempts have been made to correlate the rapidly developing *in vivo* actions of
4 GBP with acute changes in sensory processing at the level of the spinal cord or cortex.

5 We find, by studying neurons obtained *ex vivo* from animals that are responding to GBP,
6 that the rapid time course of its *in vivo* anti-allodynic effect coincides temporally with altered
7 synaptic transmission within the dorsal horn. Further analysis of rapidly developing GBP actions
8 in *substantia gelatinosa ex vivo* suggest that i) they are mediated via an intracellular interaction,
9 ii) they involve actions on the neurotransmitter release machinery iii) they involve differential
10 effects on excitatory and inhibitory neurons.

11 It is possible that the GBP-induced increase in paw withdrawal threshold in nerve
12 damaged animals (Hunter, et al., 1997;Kayser and Christensen, 2000;Field, et al., 2006;Kumar,
13 et al., 2013;Alles and Smith, 2016;Luo, et al., 2002) is a simple reflection of attenuation of spinal
14 withdrawal reflexes rather than the attenuation of pain *per se*. We therefore examined whether an
15 acute behavioral drug response could be correlated with alterations in the response of the
16 somatosensory cortex (S1) to vibrotactile stimulation (Potter, et al., 2016). S1 is a component of
17 the “pain matrix” (Legrain, et al., 2011;Eto, et al., 2011). It is involved in processing sensory-
18 discriminative aspects of both painful and non-painful touch (Komagata, et al., 2011). Structural changes
19 in S1 neurons have been reported to correlate with chronic neuropathic pain states (Kim, et al., 2012). We
20 found that vibrotactile stimulation of the limb ipsilateral to sciatic CCI produced robust S1
21 activation that was attenuated by the acute administration of GBP. A preliminary report of some
22 of these findings has appeared (Alles, et al., 2015).

23

24

1 **2. Materials and Methods**

2 All animal experiments were approved by the University of Alberta Health Sciences
3 Animal Welfare committee in accordance of the guidelines of the Canadian Council on Animal
4 Care.

5
6 *2.1 Surgery-Chronic Constriction Injury (CCI)*

7 Fifty six male Sprague Dawley rats (21-23d) were subject to 7-10d chronic constriction
8 injury (CCI) of the sciatic nerve (Mosconi and Kruger, 1996) as described previously
9 (Balasubramanyan, et al., 2006). Briefly, the left sciatic nerve of rats under isoflurane anesthesia
10 (5% induction, 2% maintenance) was exposed at mid-thigh level and two PE 90 polyethylene
11 cuffs (ID 0.86 mm, OD 1.27 mm) were slit open on one side and gently attached around the
12 sciatic nerve. The wound was closed with a silk suture, In the case of sham surgery, Forty six
13 male rats (21-23d) were anesthetized under isoflurane and the sciatic nerve was exposed, but not
14 touched with the forceps.

15
16 *2.2 Surgery - Spared Nerve Injury (SNI)*

17 Following isoflurane anesthesia as described above, eight male Sprague Dawley rats were
18 subject to spared nerve injury (SNI) (Decosterd and Woolf, 2000;Pertin, et al., 2012). An
19 incision was made through the *biceps femoris* to expose the sciatic nerve and the three terminal
20 branches: the sural, common peroneal, and tibial The SNI procedure involved the ligation and
21 transection of the common peroneal and tibial nerve, while leaving the third sural nerve intact
22 Both the common peroneal and tibial nerves were tightly ligated with 5.0 silk and sectioned

1 approximately 5 mm distal to the ligation A 2-4mm segment was removed from the distal
2 portion of the nerve stumps using care to avoid making unwanted contact with the sural nerve.
3 Finally, the muscle and skin were closed in two layers, using sutures and wound clips,
4 respectively

6 *2.3 Behavioral Testing*

7 Male Sprague-Dawley rats were tested for mechanical allodynia and hyperalgesia at 7-12
8 days after surgery (Fig 1a) using von Frey filaments of 1.4 g, 2 g, 4 g, 6 g, 10 g and 15 g weights.
9 Animals were tested prior to and 30min after injection of 100mg/kg GBP or saline (Fig 1a). This
10 dose is submaximal for the relief of inflammatory pain (Field, et al., 1997) and corresponds to
11 the 90mg/kg dose which blocks ectopic nerve injury in nerve injured rats without effect on
12 nerves from uninjured animals (Pan, et al., 1999). For testing, animals were placed in a
13 plexiglass box with a wire-grid bottom, and pressure was applied to the mid-plantar area-of the
14 left paw (injured side) starting with a von Frey filament of the lowest weight (1.4 g) until it bent
15 and then was held in this position for 2 seconds. This was performed 5 times and a positive result
16 for each hair would be given if the animal withdrew its paw a minimum of 3 out of 5 times. If a
17 negative result was obtained, the next heaviest filament would be used. A recovery period of at
18 least 1 min between was allowed between successive filament applications. The paw withdrawal
19 threshold (PWT) was calculated based on the weight of von Frey filament that elicited a positive
20 result. Rats with a paw withdrawal threshold of 6 g or less were considered to be exhibiting
21 mechanical allodynia (Balasubramanyan et al., 2006).

22
23
24

1 2.4 Preparation of acute spinal cord slices.

2 7-12 d after CCI or sham-surgery, animals were tested behaviourally for the presence of
3 allodynia. Those exhibiting a PWT <6g received an IP injection of 100mg/kg GBP or control
4 injection of saline. Following behavioural confirmation of an antiallodynic effect of GBP,
5 animals were anesthetized with a large overdose of intra-peritoneal urethane (1.5 g/kg). Because
6 animals developed allodynia at different rates and experiments were done on 6 animals per
7 batch, it was possible to stagger electrophysiological analysis over a 5-6d period. This meant the
8 youngest animals tested were 28d old (surgery at 21d, 7d to develop allodynia, tested
9 immediately) and oldest were 40d (surgery at 23d, 12d to develop allodynia, tested 5d later).

10 Following anesthesia and the cessation of cardiac contraction and loss of ocular reflexes,
11 the spinal cord was removed via laminectomy and transferred to partly-frozen, 'slushy' artificial
12 cerebrospinal fluid (aCSF) containing (in mM): 118 NaCl, 2.5 KCl, 26 NaHCO₃, 1.3 MgSO₄, 1.2
13 NaH₂PO₄, 1.5 CaCl₂, 5 MgCl₂, and 25 D-glucose, 1 kynurenic acid. Which was continuously
14 bubbled with carbogen (95% O₂, 5% CO₂). The L4-L7 region of the cord was glued with
15 cyanoacrylate glue to a trapezoid-shaped block made out of 4% agar. Transverse slices (300 μm)
16 were cut using a Microm HM 650V vibratome (Thermo Scientific, Waltham, MA, USA). Slices
17 (6-8 per animal) were incubated in ~200mls aCSF (without kynurenic acid) at 37°C for 1 hr prior
18 to recording and then stored at room temperature (22-24°C) for the remainder of the
19 experimental day (Moran et al., 2004). Slices were thus examined between approximately 200
20 and 360min following euthanasia (Fig 1a). Recordings were made from the *substantia*
21 *gelatinosa*, which was identified by its translucent appearance under IR-DIC (infrared-
22 differential interference) optics and were made from the side ipsilateral to the sciatic injury. The

1 side ipsilateral to the nerve injury was marked by cutting a longer piece of agar along the desired
2 side of the spinal cord after slicing was complete.

3

4 *2.5 Calcium imaging of acutely isolated spinal cord slices.*

5 During calcium imaging, slices were perfused at room temperature (22-24°C) with 95%
6 O₂ - 5% CO₂ saturated aCSF containing (in mM): 127 NaCl, 2.5 KCl, 1.2 NaH₂PO₄, 26
7 NaHCO₃, 1.3 MgSO₄, 2.5 CaCl₂ and 25 D-glucose, pH 7.4. Acute spinal cord slices were imaged
8 using a scanning confocal microscope (Olympus FV300) connected to an Argon laser (488 nm)
9 for confocal (single-photon) imaging using a 20× objective (Olympus NA 1.0) and 2–3× optical
10 zoom at full-frame (512 × 512 pixels). Neurons were visualized using the membrane-permeable
11 Ca²⁺ indicator dye Fluo-4 acetoxymethyl ester (AM). An increase in Fluo-4 AM fluorescence
12 intensity in response to laser excitation represented a Ca²⁺ rise. The acquisition speed was set at
13 1.08 frames per second.

14 Dorsal horn neurons were loaded with Fluo-4 AM by pressure injection (25-50 mmHg)
15 using a broken patch electrode (outer tip diameter of 5-15 μm) at a depth of 50 μm The pressure
16 injection was applied continuously for 20 min before a desired level of loading was achieved.
17 Occasionally, more than one injection attempt was required. A desired level of loading was
18 defined as at least 5 clearly visible dorsal horn cells and their basic morphology in a given field
19 of view of 200-350 μm diameter.

20 Regions of interest (ROI) were drawn around individual cell bodies in the field of view
21 and fluorescence traces were acquired using FluoView. The numerical values corresponding to
22 the fluorescence traces were then exported to Microsoft Excel. Origin 2015 (Origin Lab Corp.,
23 Northampton, MA, USA) was used for measurement of normalized fluorescence ((F_{max} – F₀)/F₀)
24 in response to stimulation with 35mM K⁺. Finally, bar graphs were constructed in Origin 2015.

1 A one-way analysis of variance (ANOVA) with Bonferroni correction was used to calculate
2 differences in $(F_{\max} - F_0)/F_0$ between CCI and sham-operated animals that had received either
3 GBP or saline.

4

5 *2.6 In vivo Two-photon Cortical Imaging*

6 This technique employs pressure injection of Ca^{2+} -indicator dyes directly into the
7 somatosensory cortex of anesthetized rats to measure rises in intracellular Ca^{2+} of individual
8 neurons in response to vibrotactile stimulation of the hind limb (Winship and Murphy, 2008).
9 CCI or sham-operated rats (30-40 days old) were affixed to a stereotaxic frame. A surgical plane
10 of anesthesia was achieved with 20% (w/v) urethane dissolved in saline and administered via
11 intraperitoneal injection (1.25 g/kg; supplemented at 0.25 g/kg as needed). Body temperature
12 was measured using a rectal probe and maintained at $37 \pm 0.5^\circ\text{C}$. An incision was made along the
13 medial portion of the scalp and the skin retracted to expose the skull. Bleeding from the scalp
14 was electro-cauterized to prevent leaking onto the exposed surface of the skull. A 4 x 4 mm
15 region of the skull overlying the right hemisphere somatosensory region was thinned to 25-50%
16 of original thickness using a high-speed dental drill (~1.5-4.5mm lateral, +1.5 to -2.5 mm
17 posterior to bregma). This thinned region was covered with 1.3% low-melt agarose dissolved in
18 aCSF at 37°C containing in mM: NaCl 135, KCl 5.4, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ 1, $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 1.8,
19 NaHEPES 5. The region was then covered with a 5mm glass coverslip. Hemodynamic intrinsic
20 optical signal (IOS) imaging was performed through this thin skull preparation before *in vivo*
21 Ca^{2+} imaging (Winship and Murphy, 2008). Imaging of intrinsic optical signals and local
22 changes in blood flow using two-photon imaging have shown that blood flow to active areas of
23 the cerebral cortex increases within 600 ms of the onset of neuronal activity (Winship, et al.,
24 2007). For IOS imaging, the cortical surface was illuminated with a red LED (635nm). Reflected

1 light was captured in 12-bit format by a Dalsa Pantera 1M60 camera mounted on a Leica SP5
2 confocal microscope. The depth of focus was set between 200-300 μm below the cortical
3 surface.

4 Custom-made piezo-electric mechanical bending actuators were used to elicit vibrotactile
5 limb stimulation (1s, 200Hz) during IOS imaging (Winship and Murphy, 2008). A total of 40
6 trials of stimulation was performed on the hindlimb contralateral (cHL) to the cortex imaged and
7 corresponding to the nerve-injured side. Placement of actuators was on the glabrous skin of the
8 cHL, with consistent alignment relative to the flexion of wrist and ankle. Images were captured
9 for 3.0s at 10 Hz (0.5s before and 2.5s after stimulus onset; inter-stimulus interval = 20s). The 40
10 trials were averaged in ImageJ software (NIH). Frames 1-1.5s after stimulus onset were averaged
11 and divided by baseline frames 0.5s before stimulus onset to generate a hindlimb response map.
12 The response map threshold was set at 50% maximal response, and overlaid on an image of
13 surface vasculature to delineate the cHL somatosensory area (Fig 1b-f). These areas were
14 subsequently used as guides for Ca^{2+} indicator injections (Winship and Murphy, 2008).

15 Subsequent to IOS imaging, the coverslip and agarose were removed. A metal plate was
16 secured to the skull using cyanoacrylate glue and dental cement and then fastened to the surgical
17 stage to prevent head movement. A 3 x 6 mm craniotomy was then performed centering over the
18 cHL functional area, determined via IOS imaging. A dental drill was used to progressively thin
19 the overlying skull until the bone could be removed with forceps, and the dura resected. The
20 exposed cortical surface was bathed in saline. Pressure injections of membrane-permeant Oregon
21 Green BAPTA-1 (OGB-1) were made 200-300 μm below the cortical surface of the HL cortical
22 region using glass micropipettes with resistances of 2-5 $\text{M}\Omega$ (Stosiek et al., 2003, Winship and
23 Murphy, 2008). Alexa-594 was used as a tracer alongside OGB-1 to determine whether dye was

1 being successfully ejected from the micropipette tip. Multiple injections were performed until a
2 desired level of loading was achieved. Typical loading is shown in Fig 1b. After OGB-1
3 injection, the cortex was incubated for 10 min with sulforhodamine 101 (SR101) dissolved in
4 DMSO to label astrocytes (Winship and Murphy, 2008, Winship et al., 2007). The craniotomy
5 was then covered with 1.3% agarose dissolved in aCSF and sealed with a glass coverslip.

6 Two-photon imaging was performed using a Leica SP5 MP confocal microscope
7 equipped with a titanium-sapphire laser tuned to 810 nm for OGB-1 and SR101 excitation. A
8 Leica HCX PL APO L 20x 1.0NA water immersion objective was used. Images were acquired
9 using Leica LAS AF using two line-averages, a zoom of 1.7x and a frame-rate of 25 Hz. Images
10 were acquired at 256 x 256 pixels over an area of 434 x 434 μ m, yielding a resolution of 1.7 μ m
11 per pixel. Ca²⁺ fluctuations in neurons and astrocytes were imaged at 130-180 μ m below the
12 cortical surface.

13 Using custom scripts written in NIH ImageJ, a median filter (radius, 1 pixel) was applied
14 to each of the image sequences of 8 trial sweeps. The 8 filtered trails were then averaged to
15 generate the final Ca²⁺ imaging frames to be analyzed. Regions of interest (ROIs) were drawn
16 around visible neurons. Astrocytes were excluded from analysis by removing ROIs that co-
17 labelled astrocytes in the SR101 channel. Numerical values representing raw neuronal
18 fluorescence traces were exported from ImageJ and were imported into Microsoft Excel. A 5-
19 point moving triangular smoothing filter was applied to each neuronal trace to increase signal-to-
20 noise ratio. We found that this triangular filter did not affect the overall amplitude or main signal
21 properties of our recorded Ca²⁺ traces, but did reduce single frame Ca²⁺ trace artifacts. $\Delta F/F_0$
22 traces were generated from the raw fluorescence traces as previously described (Winship and
23 Murphy, 2008). Neuronal Ca²⁺ signals were exported from Microsoft Excel and analyzed in

1 Clampfit 9.0 (Molecular Devices, Silicon Valley, CA, USA). Due to the large number of signal
2 traces that required analysis, various threshold criteria were tested to differentiate responsive
3 from un-responsive neurons (Winship and Murphy, 2008). A threshold criterion requiring the
4 neuronal Ca^{2+} fluorescence to increase by 3-times the standard deviation of the baseline period
5 (baseline defined as 1s before stimulus onset), and remain above this criteria for 160ms (4
6 successive frames), was found to be optimal for separating responsive neurons from noise (Fig
7 1d). Neuronal traces that met these criteria were included in subsequent analysis.

8 The index of excitability used for cortical excitability was the ‘neural mass’ or the
9 fraction of responsive cells multiplied by the mean normalized response (Doetsch, 2000,
10 Erickson, 1986). This measure provided a more suitable parameter for comparing neuronal
11 population coding and excitability of the PSC between different animals.

12 A one-way analysis of variance (ANOVA) with Bonferonni correction was used for
13 comparing the neural mass between animals. Statistical significance was attributed if $p < 0.05$.

14

15 *2.7 Measurement of GBP Levels*

16 21-30 day old Sprague-Dawley rats received either saline, 60 mg/kg GBP or 100 mg/kg
17 GBP via intraperitoneal injection. After approximately 30 min, animals were anesthetized with a
18 large overdose of intra-peritoneal urethane (1.5 g/kg) and spinal cords removed via laminectomy
19 as described above. Whole brain was removed by making an incision along the midline of the
20 head, peeling back the skin, cutting open the skull and dissecting out the brain.

21 Whole spinal cord or brain were frozen on solid CO_2 and stored in isopentane at -80°C .
22 Individual $300\mu\text{m}$ transverse spinal cord slices were prepared as described above from rats that
23 had received 100mg/kg IP GBP 30min prior to euthanasia. They were subjected to the full

1 protocol slice preparation for electrophysiology (Fig 1a) prior to freezing on solid CO₂ and
2 storage in isopentane for subsequent GBP measurement. All measurements were thus made from
3 slices frozen approximately 155min following *in vivo* drug injection (Fig 1a).

4 At the time of analysis, samples were homogenized in ice cold methanol. For a standard
5 control, 100 µl of the homogenate from saline-injected animal brain or spinal cord homogenate
6 was used and for comparison, 100 µl of homogenate from GBP-injected animal brain or spinal
7 cord homogenate was used in analysis. Samples were vortexed, placed on ice for 10 min and
8 centrifuged at 10,000 g for 4 min. A calibration curve consisting of varying amounts of authentic
9 GBP added to drug-free naive homogenates was run in parallel with each run.

10 The supernatant was transferred to a low volume silanized glass insert and 20µl of
11 supernatant was injected onto the LCMS. Analysis was performed using a Waters ZQ Mass
12 detector fitted with an ESCI Multi-Mode ionization source and coupled to a Waters 2695
13 Separations module (Waters, Milford, MA, USA). Mass Lynx 4.0 software was used for
14 instrument control, data acquisition and processing. HPLC separation was performed on an
15 Atlantis dC18 (3µm, 3.0 x 100mm) column (Waters, Milford, MA, USA) with a guard column of
16 similar material. Mobile phase A consisted of 0.05% formic acid in water and mobile phase B
17 was composed of 0.05% formic acid in acetonitrile. Initial conditions were 80% A and 20% B at
18 a flow rate of 0.3ml/min. A gradient was run increasing to 80% B in 15 min followed by a return
19 to initial conditions. The column heater and sample cooler were held at 30 °C and 4 °C
20 respectively. Optimized positive electrospray parameters were as follows: capillary voltage
21 3.4kV; Rf lens voltage 1.0 V; source 110 °C; desolvation temperature 350 °C; cone gas flow
22 (nitrogen) 100L/Hr; desolvation gas flow (nitrogen) 500 L/Hr. Cone voltage was held at 20 V.

1 Acquisition was done in the Single Ion Monitoring (SIM) mode and the mass:charge ratio was
2 set at 171.2 to correspond to the molecular weight of GBP.

3

4 *2.8 Electrophysiology*

5 Acutely isolated spinal cord slices were superfused at room temperature (22-24°C) with
6 95% O₂ - 5% CO₂ saturated aCSF. The *substantia gelatinosae* were visualized under IR-DIC
7 (infrared-differential interference) optics as a translucent band. Pipettes for recording had a
8 resistance of 6-8 MΩ when filled with an internal solution that contained (in mM): 130
9 potassium gluconate, 1 MgCl₂, 2 CaCl₂, 10 HEPES, 10 EGTA, 4 Mg-ATP and 0.3 Na-GTP, pH
10 7.18-7.20, 290-300 mOsm.

11 An NPI SEC-05LX amplifier was used for recording in discontinuous, single electrode,
12 current or voltage-clamp mode. Only data from neurons that produced a clear action potential
13 overshoot of greater than 60 mV in amplitude were collected and data were collected from just
14 one neuron per slice. Neurons were characterized on the basis of firing pattern in response to 800
15 ms depolarizing current pulses from a holding potential of -60 mV according to criteria in
16 Balasubramanian *et al.*, (2006) as either tonic, delay, phasic, transient or irregular. For
17 measurement of excitability, current ramp commands were applied and discharge rates were
18 analyzed as cumulative latency plots (Stemkowski and Smith, 2012). Current ramps were
19 delivered at 33, 67, 100 or 133 pAs⁻¹. Only the 133 pAs⁻¹ was used in analysis as this provided
20 more discharge pattern data for comparison between cell types.

21 Spontaneous excitatory post-synaptic currents (sEPSCs),-were recorded at -70 mV.
22 Miniature excitatory post-synaptic currents (mEPSCs), were recorded in the same way but in the
23 presence of 1 μM TTX. All sEPSC and mEPSC were examined and visually accepted or rejected
24 based on visual examination. Acceptable events had a sharp onset and exponential offset, a total

1 duration of <50 ms and an amplitude at least double the baseline noise. 3 min recordings were
2 analyzed from each neuron.

3

4 *2.9 Drugs and Chemicals*

5 TTX was from Alomone Laboratories, Jerusalem, Israel. Kynurenic acid (Tocris) was
6 from Cedarlane Laboratories (Hornby, Ontario, Canada). Gabapentin was from TTCI America,
7 (Portland, Oregon, USA). Fluo-4 AM cell permeant, Oregon Green 488 Bapta-1 and
8 sulforhodamine (SR-101) were from Molecular Probes, Invitrogen, Carlsbad, CA, USA. All other
9 drugs and chemicals were from Sigma, St. Louis, MO, USA.

10

11 *2.10 Data Analysis Software*

12 All data and statistical analysis was performed using Origin 2015 (Origin Lab Corp.,
13 Northampton, MA, USA, www.originlab.com), except analysis of sEPSCs and mEPSCs which
14 was performed using MiniAnalysis (Synaptosoft, Decatur, GA, USA, www.synaptosoft.com)
15 and analysis of current ramp data which was performed using pCLAMP 8.0 (Molecular Devices
16 Sunnyvale, CA, USA).

17

18 **3. Results.**

19

20 *3.1 A single IP injection of GBP increases paw withdrawal threshold in neuropathic rats within* 21 *30 min.*

22 We have shown previously that a single intraperitoneal injection of 100 mg/kg GBP in
23 neuropathic CCI rats significantly increases the PWT within 30 min (Alles and Smith 2016). In
24 confirmation of this, Fig 2a illustrates the increase in withdrawal threshold in rats subject to CCI

1 30min after IP injection of 100 mg/kg GBP (n=23) but not after injection of saline. Sham
2 operated rats exhibited a withdrawal threshold of 15.0 ± 0.0 g after saline injection (n = 18) and
3 this was unchanged in sham animals that had received GBP injection (15.0 ± 0.0 , n=21).

4 One in 6 rats that underwent CCI surgery did not develop mechanical allodynia and these
5 rats are called ‘non-responders’. As another form of control for comparison to neuropathic rats,
6 we performed experiments on non-responder rats and established that IP GBP did not have a
7 significant effect on PWT compared to saline (Fig 2a).

8 We also confirmed that IP injection of 100mg/kg GBP rapidly attenuated allodynia
9 (increased PWT) in 12 rats subject to spared nerve injury (SNI, Fig 2b). GBP did not affect PWT
10 in sham operated rats (n=4). This model produces mechanical allodynia which persists for 30
11 weeks or more (Decosterd and Woolf, 2000) whereas that accompanying CCI abates within 20
12 weeks (Luo, et al., 2001).

13

14 3.2. *Gabapentin administration reduces ex vivo dorsal horn excitability in rats subjected to CCI.*

15 Rapid antiallodynic actions of GBP in nerve-injured rats *in vivo* have been associated
16 with a decrease in glutamate release in the spinal dorsal horn (Coderre, et al., 2005). GBP would
17 thus be expected to produce an overall decrease in excitability. To test this, we first examined the
18 overall excitability of spinal cord slices obtained *ex vivo* from sham operated animals and those
19 subject to CCI. Excitability was assessed by monitoring Ca^{2+} influx in response to depolarising
20 35mM K^+ challenges. In line with previous observations that CCI increases excitatory synaptic
21 transmission and reduces inhibitory synaptic transmission in the spinal dorsal horn (Coull, et al.,
22 2003;Balasubramanyan, et al., 2006) we found that slices from “neuropathic” animals subject to
23 CCI were more excitable than those from sham operated animals ($p<0.001$ Fig. 2c). In other CCI

1 animals we administered GBP (100mg/kg IP) prior to euthanasia and the generation of spinal
2 cord slices. This prior injection of GBP attenuated excitability of slices from neuropathic animals
3 ($p < 0.001$) whereas slices from sham operated animals were unaffected (Fig. 2c). Figure 2d
4 illustrates superimposed sample recordings of K^+ -evoked Ca^{2+} responses from 36 neurons in 3
5 spinal cord slices obtained from an animal that was injected with saline before euthanasia and
6 generation of slices and responses of 34 neurons from another animal that had received
7 100mg/kg GBP. The black lines are averages of the illustrated records. Responses from GBP
8 injected animals are smaller than those from saline injected animals.

9

10 3.3 GBP levels in spinal cord (whole cord and slices) and brain of IP injected animals

11 Levels of GBP peak in CNS tissues nwithin 1.5 h of intravenous injection or oral
12 administration (Larsen, et al., 2016). We detected 1.89 μ g and 1.99 μ g of GBP per gram wet
13 weight of spinal cord or brain respectively 45min after IP injection of 100mg/kg GBP. We also
14 detected 0.55 μ g and 0.66 μ g of GBP per gram of spinal cord or brain respectively following IP
15 injection of 60mg/kg GBP. The lack of effect of GBP on paw withdrawal threshold in sham
16 operated animals is unlikely to reflect lack of penetration of the spinal cord and brain by GBP
17 and may rather reflect an absence of effect on neurons from uninjured animals.

18 Generation of *ex vivo* spinal cord slices takes approximately 200 min following GBP
19 injection (Fig 1a). For part of this time, slices are kept in a dissection solution at 37°C for
20 equilibration. We therefore tested whether the depression of dorsal horn excitability seen *ex vivo*
21 following a prior *in vivo* injection could be attributed to the continued presence of GBP in the
22 slices. This appeared to be the case as $0.54 \pm 0.07\mu$ g/g, GBP was detected in slices from the

1 lumbo-sacral region of spinal cord neuropathic animals that had received 100 mg/kg GBP
2 (n=12).

3

4 3.4 *GBP has different effects on inhibitory versus excitatory neurons.*

5 The spinal dorsal horn contains a variety of neuronal types which can be classified
6 according to their morphology, neurotransmitter content and electrophysiological properties
7 (Todd, 2010;Stebbing, et al., 2016). To an extent, morphology correlates with firing pattern and
8 neurotransmitter content (Punnakkal, et al., 2014;Todd, 2010;Yasaka, et al., 2010). For example,
9 neurons with an islet cell morphology are often GABAergic (Todd and Spike, 1993) and often
10 display a tonic discharge pattern (Grudt and Perl, 2002;Labrakakis, et al., 2009). Neurons with a
11 “delay” firing pattern are often excitatory (Punnakkal, et al., 2014). We have demonstrated that
12 long term (4-5d) exposure of dorsal horn neurons in organotypic culture to gabapentinoids is
13 more effective in inhibiting excitatory synaptic drive to putative excitatory delay firing neurons
14 than to putative inhibitory tonic firing neurons (Biggs et al 2014). To determine whether IP GBP
15 has similar, yet rapidly developing, differential effects on input to excitatory versus inhibitory
16 neurons, we examined its *ex vivo* effects on spontaneous synaptic transmission in tonic neurons
17 and in delay firing neurons. Neurons were classified according to firing pattern using criteria
18 defined in our previous work (Balasubramanian et al., 2006). In a sample of 122 neurons, we
19 found 36% tonic, 27% delay, 20.5% transient, 12.5% phasic and 4% irregular firing.

20 3.4.1. *Effects of GBP on sEPSCs in Delay Neurons.* Fig 3a illustrates the typical
21 discharge pattern of a putative excitatory delay neuron. Prior injection of 100mg/kg GBP
22 reduced average sEPSC amplitude in delay neurons from $26\pm 2.4\text{pA}$ (n=7 neurons in 7 slices) to
23 $23\pm 3.3\text{pA}$ (n=6 neurons in 6 slices; $p<0.05$). The reduction in sEPSCs amplitude in rats that had
24 received GBP and those had received saline is illustrated in a cumulative probability plot (Fig

1 3b) where $p < 0.001$, (K-S test). GBP also reduced average sEPSC frequency (increased
2 interevent interval, IEI) from 905 ± 62 ms ($n=7$) to 1435 ± 81 ms ($n=6$, $p < 0.05$). Plotting the data as
3 a cumulative probability plot (Fig 3c) yielded $p < 0.001$ (KS statistics).

4 *3.4.2. Effects of GBP on sEPSCs in Tonic Neurons.* Figure 3d illustrates the typical
5 discharge pattern of a putative inhibitory tonic neuron. By contrast with its action on delay
6 neurons, GBP did not reduce sEPSC amplitude in tonic neurons (25 ± 8.4 pA, $n=10$ in saline
7 injected animals, 25 ± 4.5 pA in GBP injected animals $n=11$, $p > 0.05$). GBP also increased the
8 frequency (decreased the interevent interval) from 4839 ± 456 ms ($n=10$) to 3015 ± 205 ms ($n=11$, p
9 < 0.05). Cumulative probability plots for the action of GBP on the amplitude and interevent
10 interval of sEPSCs in tonic neurons are shown in Fig 3e and f. The decrease in interevent interval
11 is significant ($p < 0.001$ KS test; Fig 3f).

12 *3.4.3. Effects of GBP on sEPSCs in Transient Neurons.* At least in mice, recent evidence
13 suggests that many transient firing neurons display an excitatory phenotype (Punnakkal et al
14 2014). We therefore examined the effect of GBP injection on their excitatory synaptic drive and
15 found that transient neurons were affected in the same way as putative excitatory delay neurons.
16 Fig 3g illustrates the typical discharge pattern of a transient neuron; threshold is
17 characteristically high and no more than a single action potential can be generated regardless of
18 intensity of depolarizing current.

19 Prior injection of 100mg/kg GBP reduced sEPSC amplitude in transient neurons from
20 animals subject to CCI from 25 ± 2.7 pA ($n=7$) to 22 ± 2.8 pA ($n=7$) ($p < 0.001$). The difference
21 between sEPSCs amplitudes in transient neurons from rats that had received GBP and those had
22 received saline is illustrated in a cumulative probability plot (Fig 3h) where $p < 0.001$, (K-S test).
23 GBP also reduced average sEPSC frequency (increased interevent interval) from 1522 ± 167 ms

1 (n=7) to 2220 ± 217 ms (n=7, $p < 0.01$). Plotting the data as a cumulative probability plot (Fig 3i)
2 yielded $p < 0.02$ (KS statistics).

3

4 *3.5 Which actions of GBP are a consequence of nerve injury?*

5 To determine which of the above described actions of GBP are contingent on nerve injury
6 we also examined its actions on sEPSC in delay, tonic and transient neurons from sham operated
7 animals.

8 In delay neurons, GBP reduced sEPSC amplitude in sham operated animals in a similar
9 fashion to its action on neurons from animals subject to CCI (Fig 3b and Fig 4a). By contrast,
10 GBP did not affect interevent interval in neurons from sham operated animals (Fig 4b). This
11 differs from its aforementioned action in delay neurons from animals subject to CCI where
12 interevent interval is increased (Fig 3c).

13 GBP did not affect sEPSC amplitude in tonic neurons from sham operated animals and
14 this corresponds with its overall lack of effect on sEPSC amplitude in tonic neurons from
15 animals subject to CCI (Figs 4c and 3e). The drug reduced sEPSC frequency (increased
16 interevent interval) in sham operated animals. This contrasted with GBP's aforementioned action
17 on tonic neurons from animals subject to CCI where frequency was increased (Fig 4d compared
18 with Fig 3f).

19 In transient neurons, GBP reduced sEPSC amplitude in sham operated neurons in a
20 similar fashion to its action on transient neurons from animals subject to CCI (Fig 4e and Fig
21 3h). By contrast, interevent interval was unchanged in transient neurons from sham operated
22 animals but was increased in neurons from animals subject to CCI (Fig 4f compared to Fig 3i).

23 From this, we can make the interim conclusion that the effects of GBP to increase
24 interevent interval (reduce sEPSC frequency) in excitatory delay and transient neurons after CCI

1 (Fig 3c and i) and its ability to decrease interevent interval (increase sEPSC frequency) in
2 inhibitory tonic cells after CCI (Fig 3f), are most pertinent to understanding its anti-allodynic
3 actions. Because GBP exerts similar effects on sEPSC amplitude in delay and transient cells
4 from sham operated and animals subject to CCI (Figs 3b and 4a; 3h and 4e), these effects may
5 have little relevance to its antiallodynic action.

6 Effects of GBP on tonic, delay and transient neurons from sham operated and CCI
7 animals are summarized in Table 1.

8

9 *3.6. Effects of GBP on mEPSCs*

10 Since GBP decreased sEPSC frequency in delay neurons (Fig 3c and 3i) and increased it
11 in tonic neurons (Fig 3f) we determined whether IP GBP had differential effects on the
12 neurotransmitter release process independent of depolarization-induced Ca^{2+} influx by
13 examining its effects on mEPSCs.

14 *3.6.1. Effects of GBP on mEPSC's in delay neurons.* For delay neurons from animals
15 subject to CCI, the effects of IP GBP on mEPSCs were similar to those on sEPSCs. Average
16 mEPSC amplitude in neurons from saline injected animals was 25.6 ± 0.3 pA (n=7) and this
17 compared with 18.9 ± 0.3 pA (n=5) in delay neurons from GBP injected animals ($P < 0.001$).
18 Average interevent interval was significantly increased ($p < 0.01$) from 1947 ± 225 ms (n=7) to
19 2873 ± 171 ms (n= 5). Similar differences were seen from cumulative probability plots where GBP
20 reduced mEPSC amplitude ($p < 0.001$, K-S test, (Fig 5a) and increased interevent interval
21 ($p < 0.002$, K-S test, Fig 5b). To provide further information about the effects of GBP on mEPSC
22 amplitude, we separated events into 5pA bins and displayed the amplitude data as a frequency
23 histogram (Fig 5c). GBP increased the number of small events and decreased the number of
24 small events.

1 3.6.2., *Effects of GBP on mEPSC's in tonic neurons* The effect of GBP on mEPSCs in
2 this population did not at all correspond with its actions on sEPSCs (compare Figs 5d and 5e
3 with Figs 3e and f). GBP thus increased mEPSC amplitude (Fig 5d, $P < 0.005$ KS test) but had
4 no effect on mEPSC interevent interval (Fig 5e). Average mEPSC amplitude in neurons from
5 saline injected animals was 22.8 ± 0.9 pA ($n=5$) and this was less than the value of 28.1 ± 1.6 pA
6 ($n=10$) in tonic neurons from GBP injected animals ($p < 0.02$), Interevent interval was not
7 significantly changed ($p > 0.05$). In tonic neurons from saline injected animals interevent interval
8 was 4808 ± 437 ms ($n=5$) compared to 5113 ± 433 ms in neurons from GBP injected animals.
9 Further analysis of the effects of GBP by means of a frequency histogram of binned event
10 amplitudes suggested that the drug increased the amplitude of large events but reduced the
11 amplitude of small events (Fig 5f).

12 Since transient firing neurons were encountered less frequently than tonic or delay firing
13 neurons, the limited number of recordings of mEPSCs we obtained from this population
14 precluded meaningful analysis of the data.

16 3.7. *Effects of GBP on Intrinsic Neuronal Properties.*

17 To determine whether IP GBP produces differential effects on the intrinsic neuronal
18 properties of putative excitatory delay and putative inhibitory tonic neurons, we studied the
19 cumulative latency of action potentials in response to depolarizing current ramps (Fig 5g and
20 5h). GBP injection increased cumulative latency of APs in delay firing neurons in animals
21 subject to CCI (Fig 5i, $p < 0.005$). Although it did not affect cumulative AP latency in tonic
22 neurons (Fig 5j, $p > 0.05$, one-way ANOVA), GBP did appear to affect the variance in latency of
23 APs. Note that error bars on data from GBP treated neurons are smaller than controls. It may

1 therefore exhibit some subtle action on spike frequency adaptation in a subpopulation of tonic
2 neurons.

3

4 3.8. GBP reduces Primary Somatosensory Cortex (S1) Excitability in Neuropathic Rats.

5 It may be argued that the observed actions of GBP on PWT in animals subject to CCI
6 (Fig 2a and b) and the corresponding changes in synaptic transmission in *substantia gelatinosa*
7 (Figs 3-) simply reflect depression of spinal reflexes rather than suppression of pain *per se*.
8 Therefore, in order to determine whether the acute actions of GBP impact a higher level of
9 somatosensory processing, we examined the effect of IP GBP on excitability of the primary
10 somatosensory cortex (S1).

11 As an index for overall network excitability in S1, we calculated the ‘neural mass’
12 (fraction of responsive neurons \times mean dF/F_0 , see Methods) before and 10 min following IP
13 GBP injection. To ensure that Ca^{2+} signals were recorded from neurons, we loaded superficial
14 layers of the cortex via bath application of sulforhodamine-101 (SR-101), which is preferentially
15 taken up by glia (astrocytes). By excluding all SR-101-loaded cells, we assumed that the
16 remainder of the Ca^{2+} signal was neuronal (Fig 6a). Fig 6b illustrates the averaged response of
17 114 neurons in S1 to vibrotactile stimulation of the limb that was subject to CCI.

18 As expected, before GBP administration, the neural mass of neuropathic CCI rats was
19 significantly higher than in sham-operated rats (i.e. S1 was hyperexcitable; $P < 0.05$, one-way
20 ANOVA with Bonferroni correction. Fig 6c). Within 10 minutes of injection, 100 mg/kg IP GBP
21 significantly reduced neural mass in neuropathic CCI rats by approximately 56% ($P < 0.05$, one-
22 way ANOVA with Bonferroni correction Fig 6c). However, neural mass in sham rats was not
23 significantly affected ($P > 0.05$, one-way ANOVA) 10 min following GBP injection.

1 **4. Discussion**

2 We confirmed that GBP increases PWT within 30 min of IP injection in CCI and SNI
3 neuropathic rats as has been reported in other pain models (Hunter, et al., 1997;Field, et al.,
4 2006;Kumar, et al., 2013) and in our previous publication (Alles and Smith, 2016). We now
5 show that this effect in CCI rats correlates temporally with an overall decrease in excitability of
6 dorsal horn and primary somatosensory cortex. Within *substantia gelatinosa*, effects of GBP
7 correspond to a decrease in excitatory drive to putative excitatory neurons.

8 From studies in hippocampal neurons, Hoppa *et al* (2012) posited that $\alpha 2\delta$ subunits
9 function through two mechanisms. “A trafficking step from the cell soma and a local step at the
10 presynaptic terminal allowing synapses to have increased exocytosis with decreased Ca^{2+}
11 influx”. We suggest that when $\alpha 2\delta 1$ levels are elevated, either in neuropathic pain models or by
12 genetic modulation (Luo, et al., 2002;Luo, et al., 2001;Bauer, et al., 2009), it is rapidly and
13 locally trafficked from the endoplasmic reticulum to the plasma membrane of primary afferent
14 nerve terminals. This process is interrupted by gabapentinoids within 30min of intraperitoneal
15 injection and accounts for the rapid actions we observe in *ex vivo substantia gelatinosa* (Figs 3-
16 5). By contrast, in the uninjured situation, the level $\alpha 2\delta 1$ in at neurotransmitter release sites is
17 governed by slower trafficking from the cell bodies to primary afferent terminals (Bauer, et al.,
18 2009). In this situation, a slower action of gabapentinoids represents the gradual depletion of
19 $\alpha 2\delta 1$ at nerve terminals over periods of several days as they do not appear to affect endocytosis
20 (Bauer, et al., 2009). This may account for the slowly developing effects observed in previous *in*
21 *vitro* studies (Biggs, et al., 2015;Biggs, et al., 2014)

22
23
24

1 *4.1. An intracellular site of in vivo GBP action.*

2 Long-term actions of GBP *in vitro* require its transport into the cytoplasm via the neutral
3 aminoacid transporter (Biggs et al., 2014; Hendrich et al 2008). We suggest that rapidly
4 developing *in vivo* effects are also mediated via an intracellular action with $\alpha 2\delta 1$. This is because
5 drug actions in *substantia gelatinosa* persist *ex-vivo* (Figs 3-5) and GBP can be detected in spinal
6 cord slices after their removal from animals that were displaying an anti-allodynic response to
7 the drug. GBP is not particularly lipophilic, so it is unlikely that its persistence in the tissue
8 reflects non-specific binding to cell membranes. The K_D for GBP binding to $\alpha 2\delta-1$ is in the
9 100nM range (Kadurin, et al., 2016; Lana, et al., 2016). Assuming a diffusion-limited association
10 rate constant of 10^6 to 10^8 per molar per second, the average bound time for a single molecule of
11 GBP would lie between 1 and 100 seconds. Since the slices (6-8 per animal) are incubated in a
12 relatively large volume of CSF (~200ml) for 60 min or more, it is very unlikely GBP remains
13 bound to an extracellular site on $\alpha 2\delta-1$ and more probable that intracellular retention accounts
14 for our observations. These observations are congruent with those of Lana et al (2016) who
15 showed that GBP displacement of thrombospondin 4 binding is effected at an intracellular site on
16 $\alpha 2\delta-1$.

17

18 *4.2. GBP has differential actions on excitatory compared to inhibitory neurons*

19 In general, GBP decreases excitatory drive to putative excitatory neurons but has weaker
20 and more complex actions on excitatory drive to putative inhibitory neurons (Table 1). This fits
21 with the observation that its rapid actions are associated with an overall decrease in excitability
22 of spinal cord slices from nerve injured animals (Fig 2c and d). It is also consistent with the
23 finding that glutamate release is decreased *in vivo* in nerve injured animals (Coderre et al., 2005)

1 and that GBP has little effect on GABA/glycine mediated mIPSCs in deep dorsal horn (Zhou and
2 Luo, 2015). Our analysis of *ex vivo* GBP actions were confined to effect on spontaneous synaptic
3 activity as the amplitudes of EPSCs evoked by dorsal root stimulation are highly variable (Lu
4 and Perl, 2005; Biggs, et al., 2014) and this precludes statistical comparison of GBP effectiveness
5 from sham operated and CCI animals. Although this means we cannot distinguish between
6 synaptic activity from primary afferents and that from other excitatory interneurons this may
7 have little bearing on the ability of GBP to damp down overall dorsal horn excitability.

8

9 *4.3. Effects of GBP on putative excitatory delay and transient neurons.*

10 We have defined excitatory neurons on the basis of the initial delay in action potential
11 discharge by depolarizing current pulses (Fig 3a). It should be noted that in a detailed
12 morphological and electrophysiological study of lamina II neurons, the delayed firing pattern
13 was only ever seen in excitatory neurons that were identified by the presence of VGLUT2
14 (vesicular glutamate transporter 2) immunoreactivity (Yasaka, et al., 2010). GBP reduced the
15 amplitude of sEPSCs in putative excitatory delay neurons from animals subject to CCI (Fig 3b).
16 It is not known whether this action is $\alpha 2\delta$ -1-dependent as it was also seen in sham operated
17 animals (Fig 4a; Table 1). Decreased sEPSC amplitude may be a consequence of decreased
18 mEPSC amplitude (Fig 5a). Because GBP increased the number of small mEPSC events while
19 decreasing the number of large events (Fig 5c) this suggests the drug acts presynaptically to
20 reduce quantal size or quantal content or both. The GBP-induced increase in IEI (decrease in
21 frequency) of sEPSCs in delay neurons (Fig 3c) is not seen in sham operated animals, (Fig 4b)
22 but corresponds to a decrease in mEPSC frequency (Fig 5b) and presumably to a presynaptic site
23 of action that appears only in neuropathic animals.

1 Although we do not have mEPSC data for GBP actions on putative excitatory transient
2 neurons, effects on sEPSC's exactly parallel those seen in delay neurons (Table 1). The
3 amplitude of sEPSC's is thus reduced in both sham operated animals and those subject to CCI
4 (Figs 3h and 4e). Interevent interval is only increased in animals subject to CCI (Fig 3i) and not
5 in shams (Fig 4f).

6 Taken together, the data from transient and delay neurons suggest that a presynaptic
7 action to attenuate release of glutamate onto putative excitatory neurons may play a major role in
8 GBP-induced decrease in dorsal horn excitability in neuropathic animals as suggested by
9 Coderre et al (2005).

10

11 *4.4. Effects of GBP on putative inhibitory tonic neurons.*

12 Yasaka *et al* (2010) identified 23 inhibitory neurons in rat lamina II by the presence of
13 immunoreactivity for the vesicular GABA transporter (VGAT). All but 2 of these cells exhibited
14 a tonic firing pattern. We therefore used the presence of a tonic firing pattern to identify
15 inhibitory neurons. GBP slightly increased the amplitude of mEPSCs in putative inhibitory tonic
16 neurons in CCI animals (Fig 5d). This is unlikely to reflect a postsynaptic effect as sEPSC
17 amplitude was unchanged (Fig 3e; Fig 4c; Table 1). It may rather reflect a presynaptic action
18 such that the amplitude of large events is increased whereas that of small events is decreased (Fig
19 5c). Regardless of the mechanism, an increase in mEPSC amplitude that is not reflected as a
20 change sEPSC amplitude is unlikely to contribute to the overall depressant and antiallodynic
21 actions of GBP.

22 GBP decreased the frequency (increased the interevent interval) of sEPSC in tonic
23 neurons from sham operated animals (Fig 4d), did not affect mEPSC frequency in CCI animals
24 (Fig 5e) yet did increase sEPSC frequency (Fig 3f). Since tonic firing cells are usually inhibitory

1 (Yasaka, et al., 2010), this latter effect is consistent with an overall decrease in *substantia*
2 *gelatinosa* excitability (Fig 2c and d). The underlying mechanism is however difficult to explain.

3 4.5. *GBP's effect on intrinsic neuronal excitability of substantia gelatinosa neurons.*

4 The *ex vivo* data presented in Figure 5i and j suggest that IP GBP has a differential but
5 rather weak effects on the excitability of delay and tonic neurons. In the first case, latency to
6 action potential discharge is increased. This suggests that delay neurons, which are mostly
7 excitatory (Punnakkal, et al., 2014; Yasaka, et al., 2010) will require a longer depolarizing
8 stimulus to generate an action potentials after GBP injection. In tonic, putative inhibitory
9 neurons, GBP reduces the cell to cell variability in cumulative latency of AP generation. It
10 remains to be determined whether these actions contribute to the overall decrease in excitability
11 seen with GBP (Fig 2c and d).

12

13 4.6. *GBP and nociceptive processing at the level of the somatosensory cortex*

14 We can never really know to what extent the effects of GBP in animals models represent
15 the antiallodynic and pain-suppressing effects observed in the clinical situation. Recent evidence
16 suggests that gabapentinoids may be effective in operant models which require cortical
17 processing of noxious stimulation (Harte, et al., 2016). The emotional experience of pain
18 involves a complex system of neural structures in the brainstem reticular formation and the
19 limbic system One such neural structure involved in affective pain processing involves the
20 anterior cingulate cortex (ACC) (Chen, et al., 2014b; Zhuo, 2008; Chen, et al., 2014a).

21 Unfortunately, for our studies these structures are too deep (>500 μm) to easily image using two-
22 photon laser scanning microscopy. However, imaging in layer II/III of S1 showed that IP
23 gabapentin rapidly depressed the activity generated by a vibrotactile stimulus (Fig 6). This
24 suggests that somatosensory activation resulting from processing of peripherally generated

1 cutaneous and proprioceptive information is elevated in untreated animals after CCI, thereby
2 leading to hyperexcitability of S1, and that this hyperexcitability is reversed by GBP. This may
3 relate to the drugs anti-allodynic action.

4 Since GBP exerts inhibitory actions on synaptic transmission in anterior cingulate cortex
5 (Chen, et al., 2014b), it remains to be determined whether the effects of GBP seen in S1 cortex *in*
6 *vivo* (Fig 6) reflect a direct action on cortical networks, and/or whether they are an “upstream”
7 consequence of inhibition at the spinal and/or thalamic level. In support of effects of
8 gabapentinoids on pain processing in subcortical structures, it has recently been shown that
9 pregabalin exerts actions on sensory processing in the ventral posterior thalamus of neuropathic
10 animals (Patel and Dickenson, 2016).

11 Our data are consistent with the idea that levels of $\alpha 2\delta$ protein dictate the *rapidity* of
12 gabapentinoid action (Alles and Smith, 2016), and this involves an intracellular action to reduce
13 glutamate release from excitatory terminals onto excitatory neurons. In addition, they provide a
14 hypothesis for understanding the slow rate of onset of gabapentinoid effect in the clinic where
15 drug effects take several days to develop (Sharma, et al., 2010). In a spinal nerve ligation model
16 of neuropathic pain, $\alpha 2\delta 1$ levels are elevated at 2-4 weeks but return to pre-injury levels with
17 time (Luo et al, 2001). If a similar situation occurs in patients and $\alpha 2\delta 1$ levels decrease with time
18 despite the chronic persistence of neuropathic pain, a slowly developing action of GBP may be
19 predicted (Alles and Smith, 2016).

20

21

22

23

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Figure Legends

Figure 1. Time course of *ex vivo* spinal cord experiments and procedure for *in vivo* imaging

a. Time course of experiments for investigating the anti-allodynic actions of GBP in *ex vivo* spinal cord. Adult male Sprague-Dawley rats were subject to CCI surgery and developed signs of neuropathic pain within 7 days as shown by a reduction in paw withdrawal threshold (PWT). Sham-operated rats were used as controls. On a given day of experiments, a rat's PWT was recorded before and after IP injection of 100 mg/kg IP GBP or saline (control). Following anesthesia, the spinal cord was removed and transverse 300 μm slices of lumbar cord prepared for Ca^{2+} imaging or electrophysiological analysis. **b.** low power image (field of view diameter = 12 mm) of thinned skull cortical preparation; red outline shows threshold area responding to contralateral hindlimb (cHL) stimulation (width approximately 1-2 mm) as measured by hemodynamic IOS imaging. **c.** 0.5s averaged IOS image of the same field of view as **c** prior to stimulation. **d.** Averaged IOS signal obtained during 1s 200 Hz vibrotactile stimulation of the cHL to allow generation of a 'somatosensory map **e.** average of 1s IOS post stimulus. **f.** Typical loading (false colour) of the cortex with OGB-1 (Ca^{2+} indicator) and with Alexa-594 (tracer) following injection into the cortex up to a depth of 300 μm .

Figure 2. Acute anti-allodynic actions of GBP and cellular correlates in the dorsal horn.

a. A single intraperitoneal injection of 100 mg/kg GBP significantly increased PWTs within 30 min in neuropathic CCI rats with no effect in non-responder rats that failed to develop allodynia following CCI. For saline injected controls n=22, for GBP injected n=23, for non-responders, saline injected n=6, for non-responders GBP injected n=6.). *One-way ANOVA with

1 Bonferroni correction, $p < 0.05$. **b.** Time course of effects of 100mg/kg on PWT of rats subject to
2 spared nerve injury (SNI). Upward arrows indicate times of single IP injections of drug, PWT
3 was measured 30min after injection PWT in sham operated animals was unchanged ($n=4$, grey
4 half filled circles). **c.** Effect of IP GBP injection on dorsal horn excitability (Ca^{2+} response to
5 35mM K^+) in neuropathic CCI versus sham-operated rats. Prior IP GBP reduces dorsal horn
6 excitability in CCI, but not sham-operated rats. The dorsal horn excitability of CCI rats was
7 higher than sham-operated rats. Controls for sham and CCI rats were injected with IP saline. All
8 experiments were performed blinded to the treatment of each rat until after analysis. CCI GBP, n
9 = 4 rats, 12 slices, 107 cells; CCI (Saline Control), $n = 3$ rats, 8 slices, 80 cells; Sham GBP, $n = 3$
10 rats, 11 slices, 79 cells; Sham (Saline control) $n = 3$ rats, 10 slices, 105 cells. *One-way ANOVA
11 with Bonferroni correction, $p < 0.05$. Data in **a,b** and **c** are presented as mean \pm SEM. **d.** Raw
12 fluorescence traces comparing the average of 35 mM K^+ -evoked Ca^{2+} responses in a saline-
13 injected (top) compared to GBP-injected (bottom) CCI neuropathic rat. Prior GBP injection
14 produces a noticeable reduction in the average amplitude of the response compared to prior
15 saline injection as shown by the black line in each case ($n=33$ neurons for control CCI trace,
16 $n=26$ for GBP injected). Calibration bar in arbitrary fluorescence units (AU) refers to both sets of
17 traces.

18
19
20 **Figure 3. Neuron Types and Effects of Prior GBP Injection on sEPSC's in Animals Subject**
21 **to CCI. a, d and g.** Sample recordings of AP discharge in delay, tonic and transient neurons in
22 response to two different depolarising current steps. Neuronal RMP was are held at -60 mV prior
23 to current injection. **b** and **c.** sEPSC amplitude and inter-event interval (IEI) of putative

1 excitatory delay neurons from CCI rats. n's for GBP-injected = 6 neurons/slices, 6 rats, 753
2 events. n's for Saline-injected = 7 neurons/slices, 7 rats, 1188 events. $p < 0.0001$ for both
3 amplitude and IEI). **e** and **f**. sEPSC amplitude and inter-event interval of putative inhibitory tonic
4 neurons from CCI rats. n's for GBP-injected = 11 neurons/slices, 10 rats, 636 events. n's for
5 saline-injected = 10 neurons/slices, 7 rats, 397 events. ($p > 0.05$ for amplitude and $p < 0.00005$ for
6 IEI). **h**. and **i**. sEPSC amplitude and IEI of putative excitatory transient neurons from CCI rats.
7 n's for GBP-injected = 7 neurons/slices, 5 rats, 685 events. n's for saline-injected = 7
8 neurons/slices, 7 rats, 859 events. For amplitude $p < 0.0001$ and for IEI $p < 0.02$). Cumulative
9 probability plots were compared with the Kolmogorov-Smirnov test and statistical significance
10 was attributed if $p < 0.05$.

11
12 **Figure 4. Effects of prior GBP injection on *substantia gelatinosa* neurons recorded *ex vivo***
13 **from sham operated rats. a.** sEPSC amplitude and **b.** inter-event interval (IEI) of putative
14 excitatory delay neurons from sham-operated rats. n's for GBP-injected = 7 neurons/slices, 5
15 rats, 99 events. n's for Saline-injected = 5 neurons/slices, 5 rats, 98 events. ($p < 0.00001$ for
16 amplitude and $p > 0.05$ for IEI). **c.** sEPSC amplitude and **d.** inter-event interval (IEI) of putative
17 inhibitory tonic neurons from sham-operated rats. n's for GBP-injected = 5 neurons/slices, 5 rats,
18 121 events. n's for Saline-injected = 7 neurons/slices, 5 rats, 315 events. ($p > 0.05$ for amplitude
19 and $p < 0.007$ for IEI). **e.** sEPSC amplitude and **f.** inter-event interval (IEI) of putative excitatory
20 transient neurons from sham-operated rats. n's for GBP-injected = 4 neurons/slices, 4 rats, 226
21 events. n's for Saline-injected = 3 neurons/slices, 2 rats, 176 events. ($p < 0.0007$ for amplitude
22 and $p > 0.05$ for IEI). Cumulative probability plots were compared with the Kolmogorov-Smirnov
23 test and statistical significance was attributed if $p < 0.05$.

24

1 **Figure 5. Effects of prior GBP injection on the neurotransmitter release process (mEPSC)**
2 **and intrinsic neuronal excitability of *substantia gelatinosa* neurons recorded *ex vivo* from**
3 **CCI rats .a. mEPSC amplitude and b. inter-event interval (IEI) of putative excitatory delay**
4 **neurons from CCI rats. n's for GBP-injected = 5 neurons/slices, 4 rats, 281 events. n's for saline-**
5 **injected = 7 neurons/slices, 4 rats, 580 events. ($p < 0.000001$ for amplitude and $p < 0.002$ for IEI).**
6 **c. Delay neuron mEPSC amplitude data re plotted as frequency histogram (bin width = 5pA). d.**
7 **mEPSC amplitude and e. inter-event interval (IEI) of putative inhibitory tonic neurons from CCI**
8 **rats. n's for GBP-injected = 10 neurons/slices, 7 rats, 322 events. n's for saline-injected = 5**
9 **neurons/slices, 3 rats, 172 events. ($p < 0.005$ for amplitude and $p > 0.05$ for IEI). f. Tonic neuron**
10 **mEPSC amplitude data re plotted as frequency histogram (bin width = 5pA). g-j Measurement of**
11 **intrinsic neuronal excitability. Depolarising current ramp command (bottom) and AP firing**
12 **pattern (top) associated with g. a typical delay firing neurons and h. a typical tonic firing neurons**
13 **of the *substantia gelatinosa*. i. cumulative latency to AP discharge is increased ($p < 0.005$) in**
14 **putative excitatory delay neurons in GBP compared to saline-injected CCI rats. n's for GBP-**
15 **injected = 7 neurons/slices, 6 rats. n's for saline-injected = 9 neurons/slices, 7 rats. j. In tonic**
16 **neurons, cumulative latency for AP discharge is not significantly affected in GBP- compared to**
17 **saline-injected CCI rats. n's for GBP-injected = 13 neurons/slices, 11 rats. n's for saline-injected**
18 **= 12 neurons/slices, 11 rats. 133 pAs-1 current ramp was used to plot cumulative latency versus**
19 **AP spike number in each case. Cumulative latency plots were compared by one-way ANOVA**
20 **with Bonferroni correction and statistical significance was attributed if $p < 0.05$.**

21
22
23
24

1 **Figure 6. *In vivo* primary somatosensory cortical imaging in neuropathic CCI rats.**
2 **a.** Loading of glial (red, left) and neuronal (green, right) cells at 100 μm depth in the primary
3 somatosensory cortex of adult male rats for *in vivo* two-photon imaging. Glial cells are loaded by
4 bath application of sulforhodamine and neuronal cells via pressure injection with Ca^{2+} indicator
5 OGB-1 AM dye. **b.** Recording of responses using *in vivo* cortical two-photon Ca^{2+} imaging.
6 Averaged normalized Ca^{2+} rise (shown in red) of a neuronal cell in response to repeated
7 vibrotactile stimulation (onset at 2s, duration of 1s) of the injury-side hindpaw at 200 Hz.
8 Sampling time = 40ms/frame, grey lines averaged data records from 9 neurons, black line is
9 average of average from 114 neurons (some non-responders) **c.** *In vivo* primary somatosensory
10 cortical imaging in neuropathic CCI rats immediately following IP GBP. 100 mg/kg
11 intraperitoneal GBP injection reduced cortical excitability (neural mass) in neuropathic CCI (n=3
12 rats) within 10 min of injection, with no significant reduction observed in sham-operated rats
13 (n=2 rats). A reduction in cortical excitability was observed in sham-operated rats at 20 min post-
14 injection with no further reduction observed in neuropathic rats compared to 10 min post-
15 injection. At 30 min post-injection there were no significant differences compared to at 20 min
16 post-injection in cortical excitability of either CCI or sham-operated rats. * $p < 0.05$, one-way
17 ANOVA with Bonferroni correction. All data are presented as mean \pm SEM.

18

1

	ACUTE EFFECT OF IP GBP ON SHAM OPERATED ANIMALS	ACUTE EFFECT OF IP GBP ON ANIMALS SUBJECT TO CCI
DELAY NEURONS		
sEPSC AMPLITUDE	↓	↓
sEPSC IEI	NO EFFECT	↑
mEPSC AMPLITUDE	Not Determined	↓
mEPSC IEI	Not Determined	↑
TRANSIENT NEURONS		
sEPSC AMPLITUDE	↓	↓
sEPSC IEI	NO EFFECT	↑
mEPSC AMPLITUDE	Not Determined	Not Determined
mEPSC IEI	Not Determined	Not Determined
TONIC NEURONS		
sEPSC AMPLITUDE	NO EFFECT	NO EFFECT
sEPSC IEI	↑	↓
mEPSC AMPLITUDE	Not Determined	↑
mEPSC IEI	Not Determined	NO EFFECT

2

3

4 **Table 1** Summary of actions of prior IP injection of 100mg/kg GBP on *ex vivo* properties of5 sEPSC's and mEPSC's in *substantia gelatinosa* neurons.

6

7

8

9

10

11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Reference List

- Alles SR and Smith PA (2016) The Anti-Allodynic Gabapentinoids: Myths, Paradoxes, and Acute Effects. *Neuroscientist* DOI: 10.1177/1073858416628793.
- Alles SRA, Bukhanova N, Bandet M, Winship IR and Smith PA (2015) Peripheral Nerve Injury Promotes Emergence of Acute, Neuron-type-specific Depressant Actions of Gabapentin in *Substantia Gelatinosa* and Primary Somatosensory Cortex. *Neuroscience 2015 Abstracts Chicago, IL: Society for Neuroscience, 2015 Online Program* No. 210.20.
- Balasubramanyan S, Stemkowski PL, Stebbing MJ and Smith PA (2006) Sciatic Chronic Constriction Injury Produces Cell-type Specific Changes in the Electrophysiological Properties of Rat *Substantia Gelatinosa* Neurons. *J Neurophysiol* **96**:579-590.
- Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, Kadurin I, Sri Ranjan Y, Fernandez-Alacid L, Millar NS, Dickenson AH, Lujan R and Dolphin AC (2009) The Increased Trafficking of the Calcium Channel Subunit $\alpha_2\delta$ -1 to Presynaptic Terminals in Neuropathic Pain Is Inhibited by the $\alpha_2\delta$ Ligand Pregabalin. *Journal of Neuroscience* **29**:4076-4088.
- Berger JV, Knaepen L, Janssen SPM, Jaken RJP, Marcus MAE, Joosten EAJ and Deumens R (2011) Cellular and molecular insights into neuropathy-induced pain hypersensitivity for mechanism-based treatment approaches. *Brain Research Reviews* **67**:282-310.
- Biggs JE, Stemkowski PL, Knaus E.E, Chowdhury MA, Ballanyi K and Smith P.A. (2015) Suppression of Network Activity in Dorsal Horn by Gabapentin Permeation of TRPV1 Channels; Implications for Drug Access to Cytoplasmic Targets. *Neurosci Lett* **584**:397-402.
- Biggs JE, Boakye PA, Ganesan N, Stemkowski PL, Lantero A, Ballanyi K and Smith PA (2014) Analysis of the long-term actions of gabapentin and pregabalin in dorsal root ganglia and substantia gelatinosa. *J Neurophysiol* **112**:2398-2412.
- Chen T, Koga K, Descalzi G, Qiu S, Wang J, Zhang LS, Zhang ZJ, He XB, Qin X, Xu FQ, Hu J, Wei F, Haganir RL, Li YQ and Zhuo M (2014a) Postsynaptic potentiation of corticospinal projecting neurons in the anterior cingulate cortex after nerve injury. *Mol Pain* **10**:33.
- Chen T, OGÇÖDen G, Song Q, Koga K, Zhang MM and Zhuo M (2014b) Adenylyl cyclase subtype 1 is essential for late-phase long term potentiation and spatial propagation of synaptic responses in the anterior cingulate cortex of adult mice. *Mol Pain* **10**:65.
- Coderre TJ, Kumar N, Lefebvre CD and Yu JS (2005) Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. *J Neurochem* **94**:1131-1139.
- Costigan M, Scholz J and Woolf CJ (2009) Neuropathic pain: a maladaptive response of the nervous system to damage. *Annu Rev Neurosci* **32**:1-32.

- 1 Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P and de Koninck
2 Y (2003) Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of
3 neuropathic pain. *Nature* **424**:938-942.
- 4 Decosterd I and Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral
5 neuropathic pain. *Pain* **87**:149-158.
- 6 Dolphin AC (2012) Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one
7 step beyond. *Nat Rev Neurosci* **13**:542-555.
- 8 Dolphin AC (2013) The alpha2delta subunits of voltage-gated calcium channels. *Biochim*
9 *Biophys Acta* **1828**:1541-1549.
- 10 Dolphin AC (2016) Voltage-gated calcium channels and their auxiliary subunits: physiology and
11 pathophysiology and pharmacology. *J Physiol* **594**:5369-5390.
- 12 Eto K, Wake H, Watanabe M, Ishibashi H, Noda M, Yanagawa Y and Nabekura J (2011) Inter-
13 regional contribution of enhanced activity of the primary somatosensory cortex to the anterior
14 cingulate cortex accelerates chronic pain behavior. *J Neurosci* **31**:7631-7636.
- 15 Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J and Singh L (1997) Gabapentin (neurontin)
16 and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. *Br J*
17 *Pharmacol* **121**:1513-1522.
- 18 Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S,
19 Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T and Williams D (2006) Identification of
20 the {alpha}2-{delta}-1 subunit of voltage-dependent calcium channels as a molecular target for
21 pain mediating the analgesic actions of pregabalin. *PNAS* **103**:17537-17542.
- 22 Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa
23 M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M,
24 Sena E, Siddall P, Smith BH and Wallace M (2015) Pharmacotherapy for neuropathic pain in
25 adults: a systematic review and meta-analysis. *Lancet Neurol* **14**:162-173.
- 26 Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R and Woodruff GN (1996) The novel
27 anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium
28 channel. *J Biol Chem* **271**:5768-5776.
- 29 Grudt TJ and Perl ER (2002) Correlations between neuronal morphology and
30 electrophysiological features in the rodent superficial dorsal horn. *J Physiol* **540**:189-207.
- 31 Harte SE, Meyers JB, Donahue RR, Taylor BK and Morrow TJ (2016) Mechanical Conflict
32 System: A Novel Operant Method for the Assessment of Nociceptive Behavior. *PLoS One*
33 **11**:e0150164.
- 34 Hendrich J, Bauer CS and Dolphin AC (2012) Chronic pregabalin inhibits synaptic transmission
35 between rat dorsal root ganglion and dorsal horn neurons in culture. *Channels (Austin)* **6**:124-
36 132.

- 1 Hendrich J, Van Minh AT, Hebllich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J,
2 Davies A and Dolphin AC (2008) Pharmacological disruption of calcium channel trafficking by
3 the $\alpha_2\delta$ ligand gabapentin. *Proc Natl Acad Sci U S A* **105**:3628-3633.
- 4 Hoppa MB, Lana B, Margas W, Dolphin AC and Ryan TA (2012) $\alpha_2\delta$ expression sets
5 presynaptic calcium channel abundance and release probability. *Nature* **486**:122-125.
- 6 Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J and Fontana DJ
7 (1997) The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic
8 pain. *Eur J Pharmacol* **324**:153-160.
- 9 Kadurin I, Ferron L, Rothwell SW, Meyer JO, Douglas LR, Bauer CS, Lana B, Margas W,
10 Alexopoulos O, Nieto-Rostro M, Pratt WS and Dolphin AC (2016) Proteolytic maturation of
11 $\alpha_2\delta$ represents a checkpoint for activation and neuronal trafficking of latent calcium
12 channels. *Elife* **5**.
- 13 Kayser V and Christensen D (2000) Antinociceptive effect of systemic gabapentin in
14 mononeuropathic rats, depends on stimulus characteristics and level of test integration. *Pain*
15 **88**:53-60.
- 16 Kim KJ, Yoon YW and Chung JM (1997) Comparison of three rodent models of neuropathic
17 pain. *Exp Brain Res* **113**:200-206.
- 18 Kim SK, Eto K and Nabekura J (2012) Synaptic structure and function in the mouse
19 somatosensory cortex during chronic pain: in vivo two-photon imaging. *Neural Plast*
20 **2012**:640259.
- 21 Komagata S, Tamaki K, Hishida R, Takeshita N and Shibuki K (2011) Nociceptive cortical
22 responses during capsaicin-induced tactile allodynia in mice with spinal dorsal column lesioning.
23 *Neurosci Res* **69**:348-351.
- 24 Kumar N, Cherkas PS, Varathan V, Miyamoto M, Chiang CY, Dostrovsky JO, Sessle BJ and
25 Coderre TJ (2013) Systemic pregabalin attenuates facial hypersensitivity and noxious stimulus-
26 evoked release of glutamate in medullary dorsal horn in a rodent model of trigeminal neuropathic
27 pain. *Neurochem Int* **62**:831-835.
- 28 Labrakakis C, Lorenzo LE, Bories C, Ribeiro-da-Silva A and De Koninck Y (2009) Inhibitory
29 coupling between inhibitory interneurons in the spinal cord dorsal horn. *Molecular Pain* **5**:24.
- 30 Lana B, Page KM, Kadurin I, Ho S, Nieto-Rostro M and Dolphin AC (2016) Thrombospondin-4
31 reduces binding affinity of [3 H]-gabapentin to calcium-channel $\alpha_2\delta$ -1-subunit but does
32 not interact with $\alpha_2\delta$ -1 on the cell-surface when co-expressed. *Sci Rep* **6**:24531.
- 33 Larsen MS, Keizer R, Munro G, Mork A, Holm R, Savic R and Kreilgaard M (2016)
34 Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory
35 Hyperalgesia Rat Model. *Pharm Res*.

- 1 Legrain V, Iannetti GD, Plaghki L and Mouraux A (2011) The pain matrix reloaded: a salience
2 detection system for the body. *Prog Neurobiol* **93**:111-124.
- 3 Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson
4 AH, Feng G and Luo ZD (2006) Calcium channel $\alpha_2\delta_1$ subunit mediates spinal
5 hyperexcitability in pain modulation. *Pain* **125**:20-34.
- 6 Li CY, Song YH, Higuera ES and Luo ZD (2004) Spinal Dorsal Horn Calcium Channel
7 $\alpha_2\delta_1$ Subunit Upregulation Contributes to Peripheral Nerve Injury-Induced Tactile
8 Allodynia. *Journal of Neuroscience* **24**:8494-8499.
- 9 Lu Y and Perl ER (2005) Modular Organization of Excitatory Circuits between Neurons of the
10 Spinal Superficial Dorsal Horn (Laminae I and II). *Journal of Neuroscience* **25**:3900-3907.
- 11 Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI and Myers RR (2002)
12 Injury type-specific calcium channel $\alpha_2\delta_1$ subunit up-regulation in rat neuropathic pain
13 models correlates with antiallodynic effects of gabapentin. *J Pharmacol Exp Ther* **303**:1199-
14 1205.
- 15 Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME and Yaksh TL
16 (2001) Upregulation of Dorsal Root Ganglion $\alpha_2\delta_1$ Calcium Channel Subunit and Its
17 Correlation with Allodynia in Spinal Nerve-Injured Rats. *Journal of Neuroscience* **21**:1868-
18 1875.
- 19 Mogil JS (2009) Animal models of pain: progress and challenges. *Nat Rev Neurosci* **10**:283-294.
- 20 Moore KA, Baba H and Woolf CJ (2002) Gabapentin -- Actions on adult superficial dorsal horn
21 neurons. *Neuropharmacology* **43**:1077-1081.
- 22 Moore RA, Wiffen PJ, Derry S, Toelle T and Rice AS (2014) Gabapentin for chronic
23 neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev* **4**:CD007938.
- 24 Mosconi T and Kruger L (1996) Fixed-diameter polyethylene cuffs applied to the rat sciatic
25 nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations.
26 *Pain* **64**:37-57.
- 27 Pan B, Guo Y, Wu HE, Park J, Trinh VN, Luo ZD and Hogan QH (2016) Thrombospondin-4
28 divergently regulates voltage-gated Ca^{2+} channel subtypes in sensory neurons after nerve injury.
29 *Pain*.
- 30 Pan HL, Eisenach JC and Chen SR (1999) Gabapentin suppresses ectopic nerve discharges and
31 reverses allodynia in neuropathic rats. *J Pharmacol Exp Ther* **288**:1026-1030.
- 32 Patel R and Dickenson AH (2016) Neuronal Hyperexcitability in the Ventral Posterior Thalamus
33 of Neuropathic Rats: Modality Selective Effects of Pregabalin. *J Neurophysiol*.
- 34 Pertin M, Gosselin RD and Decosterd I (2012) The spared nerve injury model of neuropathic
35 pain. *Methods Mol Biol* **851**:205-212.

- 1 Pitcher GM and Henry JL (2008) Governing role of primary afferent drive in increased
2 excitation of spinal nociceptive neurons in a model of sciatic neuropathy. *Exp Neurol* **214**:219-
3 228.
- 4 Potter LE, Paylor JW, Suh JS, Tenorio G, Caliaperumal J, Colbourne F, Baker G, Winship I and
5 Kerr BJ (2016) Altered excitatory-inhibitory balance within somatosensory cortex is associated
6 with enhanced plasticity and pain sensitivity in a mouse model of multiple sclerosis. *J*
7 *Neuroinflammation* **13**:142.
- 8 Punnakkal P, von SC, Haenraets K, Wildner H and Zeilhofer HU (2014) Morphological,
9 Biophysical and Synaptic Properties of Glutamatergic Neurons of the Mouse Spinal Dorsal
10 Horn. *J Physiol* **592**:759-776.
- 11 Sandkuhler J (2009) Models and mechanisms of hyperalgesia and allodynia. *Physiol Rev* **89**:707-
12 758.
- 13 Sharma U, Griesing T, Emir B and Young JP, Jr. (2010) Time to onset of neuropathic pain
14 reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful
15 diabetic peripheral neuropathy and postherpetic neuralgia. *Am J Ther* **17**:577-585.
- 16 Stebbing MJ, Balasubramanyan S and Smith PA (2016) Calbindin-D-28K like immunoreactivity
17 in superficial dorsal horn neurons and effects of sciatic chronic constriction injury. *Neuroscience*
18 **324**:330-343.
- 19 Stemkowski PL and Smith PA (2012) Long-term IL-1beta exposure causes subpopulation-
20 dependent alterations in rat dorsal root ganglion neuron excitability. *J Neurophysiol* **107**:1586-
21 1597.
- 22 Todd AJ (2010) Neuronal circuitry for pain processing in the dorsal horn. *Nat Rev Neurosci*
23 **11**:823-836.
- 24 Todd AJ and Spike RC (1993) The localization of classical transmitters and neuropeptides within
25 neurons in laminae I-III of the mammalian spinal dorsal horn. *Prog Neurobiol* **41**:609-645.
- 26 Torrance N, Smith BH, Bennett MI and Lee AJ (2006) The epidemiology of chronic pain of
27 predominantly neuropathic origin. Results from a general population survey. *J Pain* **7**:281-289.
- 28 Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P,
29 Hughes R, Nurmikko T and Serra J (2008) Neuropathic pain: Redefinition and a grading system
30 for clinical and research purposes. *Neurology* **70**:1630-1635.
- 31 Winship IR and Murphy TH (2008) In vivo calcium imaging reveals functional rewiring of
32 single somatosensory neurons after stroke. *J Neurosci* **28**:6592-6606.
- 33 Winship IR, Plaa N and Murphy TH (2007) Rapid astrocyte calcium signals correlate with
34 neuronal activity and onset of the hemodynamic response in vivo. *J Neurosci* **27**:6268-6272.

1 Yasaka T, Tiong SY, Hughes DI, Riddell JS and Todd AJ (2010) Populations of inhibitory and
2 excitatory interneurons in lamina II of the adult rat spinal dorsal horn revealed by a combined
3 electrophysiological and anatomical approach. *Pain* **151**:475-488.

4 Zamponi GW, Striessnig J, Koschak A and Dolphin AC (2015) The Physiology, Pathology, and
5 Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.
6 *Pharmacol Rev* **67**:821-870.

7 Zhou C and Luo ZD (2015) Nerve injury-induced calcium channel alpha-2-delta-1 protein
8 dysregulation leads to increased pre-synaptic excitatory input into deep dorsal horn neurons and
9 neuropathic allodynia. *European Journal of Pain* Feb 17. doi: 10.1002/ejp.656. [Epub ahead of
10 print].

11 Zhuo M (2008) Cortical excitation and chronic pain. *Trends Neurosci* **31**:199-207.

12
13
14

15 **ACKNOWLEDGEMENTS**

16 We thank Gail Rauw, Nataliya Bukhanova, Twinkle Joy and Bin Dong for technical assistance.
17 Supported by the Natural Sciences and Engineering Research Council (NSERC, Ottawa, ON
18 Canada) and by the Canadian Foundation for Innovation (CFI) awards to PAS and KB

19

20 **AUTHORSHIP CONTRIBUTIONS**

21 *Participated in research design:* Alles, Bandet, Winship, Baker, Ballanyi, Smith

22 *Conducted Experiments:* Alles, Bandet, Noh, Eppler

23 *Performed Data Analysis:* Alles, Bandet Eppler

24 *Wrote or contributed to the writing of the manuscript:* Alles, Smith, Eppler

25 *Developed Methodologies and Provided Additional Laboratory Facilities:* Ballanyi, Noh, Baker,
26 Winship

27

28





Figure 1




Figure 2




Figure 3






Figure 4


a Delay mEPSC Amplitude (CCI)






d Tonic mEPSC Amplitude (CCI)




b Delay mEPSC IEI (CCI)




e Tonic mEPSC IEI (CCI)




g Delay AP's (CCI)



h Tonic AP's (CCI)



i Delay Excitability (CCI)



j Tonic Excitability (CCI)




Figure 5




Figure 6